Apart from the emerging sensitivity biomarkers identified through synthetic lethal interactions with PARP inhibitors [1, 2,7,8,12,34-38], several molecular determinants of enhanced resistance in BRCA-deficient tumours, such as revertant BRCA gene mutations, loss of p53BP1 or JMJD1C have been reported and their predictive value requires careful evaluation [2,34,39-41]. This evidence concerns the gene PARP1 and neoplasm.